Insulet Corp (NASDAQ: PODD) is a medical device company that designs, manufactures, and sells insulin delivery systems for people with diabetes. Revenue is generated primarily through the recurring sale of disposable pod consumables that users replace every few days, creating a high-frequency consumable revenue stream tied to an installed base of active users. The flagship product is the Omnipod system, a tubeless, wearable insulin pump that attaches directly to the body without traditional tubing. Because users must continuously reorder pods to manage their condition, the business carries meaningful switching-cost characteristics once a patient is trained on the platform. The filing was made on 2026-02-18 for the fiscal year ended in that period. Specific segment revenue percentages, user counts, and geographic revenue breakdowns are not supported by the excerpts provided and are therefore omitted.

Revenue model

Recurring consumable sales: users purchase disposable Omnipod pods on an ongoing basis, generating a repeat-purchase revenue stream tied to the active user base. The model resembles a razor-and-blade structure where the reusable Personal Diabetes Manager or app-based controller drives continuous pod repurchase.

Products and services

Omnipod insulin delivery system, including disposable tubeless pods and associated controllers or app-based management software.

Customers and end markets

People with insulin-dependent diabetes, primarily Type 1 and Type 2 diabetes patients. Distribution occurs through pharmacy and durable medical equipment channels.

Value-chain role

Medical device manufacturer and direct seller of insulin delivery consumables and systems.

Geographic exposure

Not supported by the filing excerpts provided.

Source: SEC 10-K, filed 2026-02-18

Industry: Surgical & Medical Instruments & Apparatus Peers: Abbott Laboratories ABIOMED INC Baxter International Inc Dexcom Inc HOLOGIC INC IDEXX Laboratories Inc Resmed Inc Shockwave Medical, Inc. Teleflex Inc Zimmer Biomet Holdings, Inc